CLINUVEL PHARMACEUTICALS WKN: A0JEGY ISIN: AU000000CUV3 Forum: Aktien Thema: Hauptdiskussion

Top 👍🏻

Danke 👍🏻

👍

https://scenesse.com/public/frequently-asked-questions/ mittlerweile 4 Behandlungszentren in den USA

Immer noch massivst historische Kaufkurse ☝🏻

https://www.change.org/p/licht-f%C3%BCr-alle-therapie-f%C3%BCr-die-seltene-lichtkrankheit-epp-endlich-zug%C3%A4nglich-machen/u/26563934?cs_tk=AlpDpnZYdn6bICeQtl4AAXicyyvNyQEABF8BvJgqFVtVa2ORSQsThRer1Co%3D&utm_campaign=c2ad40dac12c40efb836c2547ccf7d9e&utm_content=initial_v0_4_0&utm_medium=email&utm_source=petition_update&utm_term=cs

historische Kaufkurse !

👍

Clinuvel jetzt wieder in Fahrt 😊 Klasse 👍

Entschuldigt falls es im 4c steht hatte nicht gesehen das er da ist..

Patientenzahlen denke ich werden noch nicht zu hoch sein wegen corona aber auch weil erst 3(?) Kliniken behandeln oder?

Danke odi Wir dürfen sehr gespannt sein, vor allem auf die Aktivitäten in den USA und die Patientenzahlen

Frogster from Sharesscene What a couple of weeks of newsflow. Quite amazing what we’ve learnt. To recap: 1) Confirmation from patients that implants are being administered in the US. 2) Commentary from the APF that CUV is working hard to open further expert centres in the US. 3) Commentary from the APF that they are seeking to help non-US based patients access Scenesse. 4) Selective disclosure by LH to PinkSheets that a dozen European countries are on-line (would be nice to get these officially detailed as a dozen is surprisingly high). 5) Surprise entry to China via limited scheme which MAY lead to full access in short order (6-9m) after trial shows no ethnic disparity in efficacy . Potentially 5,000 patients i.e. of the same order as the US market. 6) CUV beginning to describe Scenesse in terms of vaso activity and anti-phlogitism at almost exactly the point we find they registered a trade-mark (Prenumbra) which just might be useful as a stroke treatment/preventative. 7) 4C cash flows show surprising resilience in the face of CV19 and plateauing Euro roll out, and currency benefits help to offset the temporary lull and actually see cash reserves climb to $62m. Pleasing to see a fuller, more complete discussion of what was behind the numbers. 8) Positive feedback from crucial FDA type C meeting which confirms a constructive relationship between the two parties and suggests that one, not two, US Vitiligo trials will suffice before an sNDA is submitted 9) Evidence that the “story” and, more importantly, the prospects over the next few years are now strong enough to attract the vey top tier of active institutional investors as GSAM increase their stake, and Capital Research, one of the most thorough fundamentals driven houses there is, leap to the top of the insto list with a 2.5% stake. It’s exhausting. In a good way. What did I miss?

https://www.asx.com.au/asx/statistics/displayAnnouncement.do?display=pdf&idsId=02231253

Wie hat Homm schon auf der World of Value gesagt, ich freue mich über noch mehr Leer Verkäufer bei CUV 🙂

Meiner Meinung nach, spätestens mit der nächsten zahlen 🙂